

DATE- 23/3/24

NAME - Komoz

PHONE - 9871528242

AGE/GENDER-tanale ADDRESS- Wo Inchagoni Touther Guspon 122414
EMAIL-PKTEK ARIA 8892@ GMAIL. CONCORPORATE NAME- BOB.

1. Past medical history & medications:-

Am xiety

2. Any existing disease: -

3. Current medications :-

- 4. VITALS (To be filled by medical personnel)
 - BLOOD PRESSURE -\Q\.../56
 - PULSE RATE 7.....
 - TEMPERATURE .97
 - SPO2 9.6.
 - BLOOD SUGAR (RANDOM)
 - HEIGHT 1.5.5.
 - WEIGHT .5......
 - . BMI 20.8.

vis100- RE-6/9 LE-619.

Colous vision- Normal.



5. FINDINGS: -

LABINVESTIGATION: - Hb - 12.20 gm/df.

PP&BS - 143.50 mg/dl. (11)

Reit invertigations - Normal.

ECG - Normal.

RADIOLOGY INVESTIGATIONS: - Sonology Breast Benign less on in left upper outer.

Quadrant & Ble Abroadenosis.

- BIRAD'S Rt - II, Left - II.

6. DOCTOR REMARKS: -

Exprecologist consultation.





CERTIFICATE OF MEDICAL FITNESS

she	reviewing the medical history and on clinical examination it has been found that is	- C-2
		T
*	Medically Fit	-
0	Fit with restrictions/recommendations	T
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
	1	
	2	
	3	1
	However the employee should follow the advice/medication that has been	
	communicated to him/her.	
	Review after	
6	Currently Unfit. Review after recommended	Ī

This certificate is not meant for medico-legal purposes

The Apollo Clinic, (Location)



3/23/2024 REPORT DATE PATIENT NAME MS KOMAL 25 YRS / F AGE/SEX P.H.M.C **REF BY**

ULTRASOUND - ABDOMEN & PELVIS

Clinical Profile-HEALTH CHECKUP.

Findings

The liver is normal in size, outline and parenchymal echotexture. No focal lesion is seen. The portal vein is normal in calibre and course.

The gall bladder shows normal contents. The intra hepatic biliary radicals and CBD are normal. The pancreas and spleen are normal.

Both the kidneys are normal in size, outline and parenchymal echopattern. No calculus, hydronephrosis or any other abnormality is seen on either side.

No free fluid is seen in the peritoneal cavity. No lymph node enlargement is seen in the para-aortic region.

The urinary bladder is normal in outline.

The uterus is normal in size with smooth outline. The myometrial echoes are homogenous and the endometrial lining is central, 9mm. Both the adnexal regions are clear without any mass or collection.

The Pouch of Douglas does not show any free fluid.

IMPRESSION-NO OBVIOUS SONOLOGICAL ABNORMALITY IS SEEN IN THIS STUDY

Clinical correlation is necessary.

DAV DR. RAJNISH JUNEJA, D.N.B (RADIO – DIAGNOSIS)

The science of radiology is based upon interpretation of shadows of normal and abnormal tissues and hence does not represent histopathology and ultimate diagnosis. Findings should always be interpreted in to the light of clinico-histo-pathological correlation. Not meant for medico legal purposes.



DATTENIT MAME	MC KOMAI	REPORT DATE	3/23/2024
PATIENT NAME		AGE/SEX	25 YRS / F
REF BY	P.H.M.C	AGL/ SLX	20 1110 /

SONOLOGICAL EVALUATION OF THE BREASTS

Scanning scheme used : longitudinal, transverse, radial & orthogonal ante-radial scan obtained using high frequency probes.

Both the breasts display decrease parenchymal echogenicity with multiple hypoechoic areas within.

A well defined lobulated hypoechoic lesion, measuring 41x23mm is seen in left upper outer quadrant. On color/power Doppler evaluation vascularity was noted in it.

Both the axillae do not reveal any significant lymphadenopathy.

IMPRESSION:

FINDINGS ARE SUGGESTIVE OF A BENIGN LESION IN THE LEFT UPPER OUTER QUADRANT WITH BILATERAL FIBROADENOSIS.

ADVISED FNAC & FOLLOW UPS.

BIRAD'S RIGHT BREAST - II

BIRAD'S LEFT BREAST - III

BIRAD'S GRADING : -

CATEGORY o	Incomplete. Needs additional imaging evaluation and / or prior films for comparison
CATEGORY 1	Negative (Normal)
CATEGORY 2	Benign Probably benign (<2% risk of malignancy) Initial short - internal follow-up suggested (6 monthly)
CATEGORY 3	
CATEGORY 4	Suspicious Abnormality
4 A	Finding needing intervention (low suspicious of malignancy)
4 B	Close radiological & pathologic correlation (Intermediate suspicious of malignancy)
4 C	Moderate concern for malignancy
CATEGORY 5	Highly suggestive of malignancy > 95%
CATEGORY 6	Known Biopsy - Proven malignancy.

DR. RAJNISH JUNEJA, D.N.B (RADIO – DIAGNOSIS)



Patient's Name:-

MS. KOMAL

Date :- 23/03/2024

Referred By :-

HEALTH CHEAKUP

Age/Sex :- 25Y/F

Radiograph of Chest (PA View)

Visualized lungs fields appear normal.

Both hila appear normal

Both CP Angle are clear.

Domes are normally placed.

Cardiac shadow appears normal.

Trachea and mediastinum are normal.

Thoracic bony cage is normal.

Please correlate clinically

Dr Arushi Gupta

MBBS, DNB (Radio - Diagnosis)

Radiologist

Date of birth 29 01 199	Wieigh ID	73 hnm			
Gender Female			824 ms	Ventricular premature complex(es)	
		000	37 ms	Sinus rhythm	
		220	140 ms	Normal electrical axis	
Ethnicity Undefined		QRS axis 86° QT	373 ms	A STOCK OF THE STO	
racemaker Unknown		. 19	411 ms	Unconfirmed report	
Indication Remark					
	v	Abnormal			
1	QV.c				
	ANA	T _N		42	
Par					1
	awl	V2		vs (<
					<u>}</u>
	ave ave	N N3	}	V6 V	
25 mm/s, 10 mm/mV		Sequential			LP 25Hz. AC 60Hz
}		< <	(-
	7				
25 mm/s. 10 mm/mV					
AT-102 G2 1.2.0 (1080:009830)	830)	Printed on 23 03 2024 11 41 32	41.32		LP 25Hz, AC 60Hz
		THE RESERVE AND THE PROPERTY OF THE PERSON O	75.11		



Patient's Name	MS KOMAL	Date	23-03-2024
Referred by	HEALTH CHECK UP	Age &Sex	25Yrs/F

MITRAL VALVE

AML - Normal / Thickening/Calcification/ Flutter/ Vegetation/ Prolapse/ SAM/ Doming Morphology

PML - Normal / Thickening / Calcification / Mild Prolapse / Paradoxical motion / fixed

Score: Sub valvular deformity Present/ Absent

Doppler Normal/Abnormal E>A

RR interval.....msec Present/Absent

A>E

Mitral Stenosis MVA.....cm² EDG....mmHg MDG.....mmHg Mitral Regurgitation Absent /Trivial/Mild/Moderate/Severe

TRICUSPID VALVE

Normal/ Atresia/Thickening/ Calcification/ Prolapse/ Vegetation/ Doming Morphology

Normal/ Abnormal Doppler

RR interval..... Tricuspid Stenosis Present/ Absent

MDG.....mmHg EDG.....mmHg

Tricuspid Regurgitation: Absent/ Trivial/ Mild/ Moderate/ Severe Fragmented signals

Velocity.....m/sec

PULMONARY VALVE

Morphology Normal/ Atresia/ Thickening/ Doming/ Vegetation

Normal/ Abnormal Doppler

Level Valvular and Sub valvular Pulmonary Stenosis Present/Absent

PV Max = 1.0 m/sec PSG.....mmHg Pulmonary annulus.....mm

Pulmonary Regurgitation Present/ Absent

End Diastolic Gradient.....mmHg Early diastolic gradient.....mmHg.

AORTIC VALVE

Normal/ Thickening/ Tip Calcification/ Restricted Opening/ Flutter vegetation Morphology

> No. of cusps 1/2/3/4

Normal/ Abnormal Doppler

Aortic Stenosis: Present/Absent

Aortic Annulus.....mm AV Max = 1.4 m/sec Aortic Regurgitation Absent/ Trivial/ Mild/Moderate/ Severe

> TO BOOK AN APPOINTMENT 08079



(1.9-4.0 cm) (3.7-5.6 cm) (0.6-1.1 cm) (up to 5 mm)

Normal/ Flat/ Paradoxical

Normal Values Measurements Measurements LAes-2.7 Aorta-2.0 (2.0-3.7 cm)(2.2-4.0 cm) LVed-3.3 LVes-2.2 IVSed-0.9 (0.6-1.1 cm) PW (LV) 0.6 RV ed (0.7-2.6 cm)RV anterior wall LVVd (ml) LVVs (ml) EF 60-65 % (54%-76%) IVS motion

CHAMBERS:

LV <u>Normal</u> / Enlarged/ Clear/ Thrombus/hypertrophy Contraction Normal / Reduced

LA Normal / Enlarged / Clear / Thrombus

RA Normal/ Enlarged/ Clear/ Thrombus

RV <u>Normal/</u> Enlarged/ <u>Clear/</u> Thrombus

Pericardium Normal/ Thickening/ Calcification/ Effusion


COMMENTS AND SUMMARY

- ALL FOUR CHAMBERS NORMAL IS SIZE AND SHAPE
- ALL FOUR VALVES NORMAL IN MORPHOLOGY
- NO MR/AR/TR
- NO AORTIC STENOSIS
- NORMAL LV DIASTOLIC FUNCTION
- NO CLOT/MASS/PE SEEN
- NORMAL LV SYSTOLIC FUNCTION, LVEF= 60-65%


Kindly correlate clinically

DR. ROHIT GOEL

M.D, D.M (Cardiology)







Konral 25/F



Pf- Cx healthy, curdy \$15 B Plv-ul upright, ~Il Car By John

Vog Ind. Comsoft CLIMSES

(or 1 23/3/224

DR. BINDU BISHT

B.D.S, MIDA, MISDT (General Dentist)



NAME:- Kerner AGE/SEX: 25 /F DATE: 23 Majo	
\mathcal{U}	
O(E) Stanley ++	
Colcular	
els adrice) (O , i d O M ,	

3 July 10



Patient NAME : MRS.KOMAL Age/Gender : 25 Y O M O D /F

LabNo : DPL23763 Referred BY

Refer Lab/Hosp : APOLLO CLINIC

: SELF

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:36PM

DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 24

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE BLOOD COUNT				
Sample Type: WHOLE BLOOD EDTA				
HAEMOGLOBIN (HB)	12.20	gm/dL	13.5 - 18.0	Cynmeth Photometric Measurement
RBC COUNT(RED BLOOD CELL COUNT)	4.2	mil/cu.mm	4.7 - 6.0	Electrical Impedence
PCV/HAEMATOCRIT	37.9	%	42-52	Calculated
MCV	89.50	fL	78-100	Electrical Impedence
MCH	28.7	pg	27-31	Calculated
MCHC	32.1	gm/dL	32-36	Calculated
RDW-SD	13.3	fL	39-46	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4760	cell/cmm	4000-10000	Electrical Impedence
NEUTROPHIL	50	%	40-80	VCSn Technology
LYMPHOCYTE	42	%	20-40	VCSn Technology
MONOCYTE	06	%	2-10	VCSn Technology
EOSINOPHIL	02	%	1-6	VCSn Technology
BASOPHIL	00	%	0-2	VCSn Technology
PLATELET COUNT	98	10^3/ul	150 - 450	Electrical Impedence
MPV	12.5	fL	7.2 - 11.7	Electrical Impedence
PCT	0.1	%	0.2 - 0.5	Calculated
PDW	17.6	%	9.0 - 17.0	Calculated
ABSOLUTE NEUTROPHIL COUNT	2.38	x10^3 Cells/uL	1.5-7.8	Automated Calculated
ABSOLUTE LYMPHOCYTE COUNT	2	x10^3 Cells/uL	2.0-3.9	Automated Calculated
ABSOLUTE MONOCYTE COUNT	0.29	x10^3 Cells/uL	0.2-0.95	Automated Calculated
ABSOLUTE EOSINOPHIL COUNT	0.1	x10^3 Cells/uL	0.2-0.5	Automated Calculated

Tests done on Automated Three Part Cell Counter. (WBC, RBC, Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo Referred BY : DPL23763

Refer Lab/Hosp

: SELF

b/Hosp : APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:59PM

DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 24

	711 OLL	.017101010121		
Test Name	Result	Unit	Bio. Ref. Range	Method
ERYTHROCYTE SEDIMENTATION RATE				
Sample Type : WHOLE BLOOD EDTA				
ERYTHROCYTE SEDIMENTATION RATE	15	mm/hr	<20	EDTA Whole blood, modified westerngren

Note:

- 1. Test conducted on EDTA whole blood at 37°C.
- 2. ESR readings are auto- corrected with respect to Hematocrit (PCV) values.
- 3. It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever. It is also increased in multiple myeloma, hypothyroidism.





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY Refer Lab/Hosp : SELF

: APOLLO CLINIC

Barcode NO : 20011725

Report Generated Date

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM

: 23/Mar/2024 07:54PM

DEPARTMENT OF HAEMATOLOGY
APOLLO PACKAGE 24

Test Name

Result

Unit

Bio. Ref. Range

Method

BLOOD GROUP ABO & RH

Sample Type: WHOLE BLOOD EDTA

ABO

"0"

Gel Columns agglutination

Rh Typing

POSITIVE

Gel agglutination

COMMENTS:

The test will detect common blood grouping system A, B, O, AB and Rhesus (RhD). Unusual blood groups or rare subtypes will not be detected by this method. Further investigation by a blood transfusion laboratory, will be necessary to identify such groups.

Disclaimer: There is no trackable record of previous ABO & RH test for this patient in this lab. Please correlate with previous blood group findings.





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo Referred BY : DPL23763

: SELE

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20011725

: 23/Mar/2024 04:24PM Registration Date

Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:50PM

DEPARTMENT OF BIOCHEMISTRY **APOLLO PACKAGE 24**

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST				
Sample Type : SERUM				
TOTAL BILIRUBIN	0.70	mg/dL	0.1-1.2	Jendrassik Grof
CONJUGATED (D. Bilirubin)	0.20	mg/dL	Adults and Children: < 0.3	Diazotization
UNCONJUGATED (I.D. Bilirubin)	0.50	mg/dL	0.1 - 1.0	Calculated
SGPT	16.00	U/L	< 45	UV with P5P, IFCC 37 Degree
SGOT	20.20	U/L	< 50	UV with P5P, IFCC 37 degree
SGOT/SGPT	1.26	Ratio	0.7 - 1.4	
GGT	18	U/L	< 55	G-glutamyl-carboxy- nitoanilide
ALKALINE PHOSPHATASE	80.00	U/L	56-119	PNPP, AMP Buffer, IFCC 37 degree
TOTAL PROTEINS	7.10	g/dL	6.6-8.3	Biuret, reagent blank end point
ALBUMIN	4.60	g/dL	Adults: 3.5 - 5.2	Bromcresol purple
GLOBULIN	2.5	g/dL	1.8 - 3.6	Calculated
A/G RATIO	1.84	Ratio	1.2 - 2.2	Calculated

Note:

Bilirubin Total

Clinical Significance: "Total Bilirubin is one of the most commonly used tests to assess liver function. A number of inherited and acquired diseases affect bilirubin production, metabolism, storage and excretion and causes hyperbilirubinemia resulting in jaundice. Hyperbilirubinemia may be due to increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Unconjugated hyperbilirubinemia is seen in newborn andd known as physiological jaundice. Elevated unconjugated bilirubin in the neonatal period may result in brain damage (kernicterus). Crigler-Najjar syndromes type I and type II are also associated with elevated levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatitis and space-occupying lesions of the liver; and obstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

Bilirubin Direct

Clinical Significance: "Direct bilirubin is a measurement of conjugated bilirubin. Jaundice can occur as a result of increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Inherited disorders in which direct bilirubin levels are increased are seen in Dubin-Johnson syndrome and Rotor syndrome, idiopathic neonatal hepatitis and biliary atresia. The most commonly occurring form of jaundice of the newborn called physiological jaundiceis due to increase in levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatocellular diseases such as hepatitis and space-occupying lesions of the liver, bstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

SGOT / AST

Clinical Significance: "Elevated aspartate aminotransferase (AST) values are seen most commonly in parenchymal liver diseases. Values can be elevated from 10 to 100 times the normal range, though commonly 20 to 50 times elevations are seen. AST levels are raised in infectious hepatitis and other inflammatory conditions



MBBS, DNB Pathology Sr. Consultant (HMC.9669)



Patient NAME : MRS.KOMAL

Age/Gender : 25 Y O M O D /F

LabNo : DPL23763

Refer Lab/Hosp : APOLLO CLINIC

: SELE

Barcode NO : 20011725

Sample Collected Date

Registration Date : 23/Mar/2024 04:24PM

: 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:50PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name Result Unit Bio. Ref. Range Method

affecting the liver along with ALT, though ALT levels are higher. The ALT:AST ratio which is normally 1. AST levels are usually raised before clinical signs and symptoms of disease appear. AST and ALT also rise in primary or metastatic carcinoma of the liver, with AST usually being higher than ALT. Elevated AST values may also be seen in disorders affecting the heart, skeletal muscle and kidney, such as myocardial infarction, muscular dystrophy, dermatomyositis, acute pancreatitis and crushed muscle injuries."

SGPT/ALT

Referred BY

Clinical Significance: Elevated alanine aminotransferase (ALT) values are seen in parenchymal liver diseases characterized by a destruction of hepatocytes. Values are at least 10 times higher the normal range and may reach up to 100 times the upper reference limit. Commonly, values are seen to be 20 - 50 times higher than normal. In infectious hepatitis and other inflammatory conditions affecting the liver, ALT levels rise more than aspartate aminotransferase (AST), and the ALT/AST ratio, which is normally 1. ALT levels usually rise before clinical signs and symptoms of disease appear.

Alkaline Phosphatase (ALP)

Clinical Significance: Alkaline Phosphatase levels can be elevated in both liver related as well as bone related conditions. ALP levels are raised (more than 3 fold) in extrahepatic biliary obstruction (eg, by stone or by cancer of the head of the pancreas) than in intrahepatic obstruction, and isdirectly proportional to the level of obstruction. Levels may rise up to 10 to 12 times the upper limit of normal range and returns to normal on surgical removal of the obstruction. ALP levels rise together with GGT levels and If both GGT and ALP are elevated, a liver source of the ALP is likely. Among bone diseases, ALP levels rise in Paget disease (up to 25 fold), osteomalacia, rickets, primary and secondary hyperparathyroidism and osteogenic bone cancer. Elevated ALP is seen in children following accelerated bone growth. Also, a 2 to 3fold elevation may be observed in women in the third trimester of pregnancy, although the interval is very wide and levels may not exceed the upper limit of the reference interval in some cases.

Total Protein

Clinical Significance: High levels of Serum Total Protein is seen in increased acute phase reactants in inflammation, late-stage liver disease, infections, multiple myeloma and other malignant paraproteinemias.n. Hypoproteinemia is seen in hypogammaglobulinemia, nephrotic syndrome and protein-losing enteropathy.

Albumin

Clinical Significance: "Hypoalbuminemia can be caused by impaired synthesis due to liver disease (primary) or due to diminished protein intake (secondary), increased catabolism due to tissue damage and inflammation; malabsorption of amino acids; and increased renal excretion (eg, nephrotic syndrome). Hyperalbuminemia is seen in dehydration."





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo Referred BY : DPL23763

Refer Lab/Hosp

: SELF : APOLLO CLINIC Barcode NO

: 20011725

Registration Date

: 23/Mar/2024 04:24PM

Sample Collected Date

: 23/Mar/2024 04:24PM

Report Generated Date

: 23/Mar/2024 05:49PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE				
TOTAL CHOLESTEROL	182.00	mg/dL	Desirable: <= 200 Borderline High: 201-239 High:>239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	Serum, Cholesterol oxidase esterase, peroxidase
TRIGLYCERIDES	61.70	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	Serum, Enzymatic, endpoint
H D L CHOLESTEROL	52.60	mg/dL	Normal: > 40 Major Heart Risk: < 40	Serum, Direct measure-PEG
L D L CHOLESTEROL	117.06	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	Serum
NON HDL CHOLESTEROL	129.4	mg/dL	Desirable: < 130 mg/dL Borderline High: 130- 159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	Calculated
VLDL	12.34	mg/dL	6 - 38	Calculated
T. CHOLESTEROL/ HDL RATIO	3.46	Ratio	3.5 - 5.0	Calculated
LDL / HDL RATIO	2.23	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - >6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated
HDL/LDL RATIO	0.45	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated





Patient NAME : N

: MRS.KOMAL

Age/Gender : $25 \ Y \ O \ M \ O \ D \ /F$

LabNo Referred BY : DPL23763

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM Report Generated Date : 23/Mar/2024 05:49PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name Result Unit Bio. Ref. Range Method





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 07:31PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

	711 011	O I MOIG IOL 2 I		
Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C				
Sample Type: WHOLE BLOOD EDTA				
HBA1c	5.3	%	Non-Diabetic: <=6.0 Pre Diabetic:6.1 - 7.0 Diabetic: >=7.0	EDTA Whole blood,HPLC
ESTIMATED AVG. GLUCOSE	104.84	mg/dL		

Interpretations

- 1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
- Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.
- Excellent control-6-7 %
- Fair to Good control 7-8 %
- Unsatisfactory control 8 to 10 %
- Poor Control More than 10 %





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 07:31PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name Result Unit Bio. Ref. Range Method

GLUCOSE - FASTING

Sample Type: FLOURIDE PLASMA

Plasma Glucose Fasting

83.6

mg/dL Normal: 70-100

ormal: 70-100 Plasma, Hexokinase

Impaired Fasting Glucose (IFG): 100-125

Diabetes Mellitus: >= 126 (On more than one occasion)

Note:

As per American Diabetic Association, (ADA) 2018 Guidelines:

Fasting Plasma Glucose Value (in mg/dl) Interpretation

- 70 100 Normal
- 101 125 IFG (Impaired Fasting Glucose)
- >/= 126 Diabetes mellitus

It is recommended that fasting plasma glucose be repeated on Two separate occasions or fasting plasma glucose with HbA1c should be done to confirm the diagnosis of Diabetes mellitus.

Fasting is defined as no caloric intake for at least 8 hours





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 07:31PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name Result Unit Bio. Ref. Range Method

GLUCOSE - PP

Sample Type: FLOURIDE PLASMA (PP)

Plasma Glucose PP **143.50** mg/dl 80-140 Glucose

Oxidase/Peroxidase

INTERPRETATION:

Increased In

- Diabetes Mellitus
- Stress (e.g., emotion, burns, shock, anesthesia)
- Acute pancreatitis
- Chronic pancreatitis
- Wernicke encephalopathy (vitamin B1 deficiency)
- Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)

Decreased In

- Pancreatic disorders
- Extrapancreatic tumors
- Endocrine disorders
- Malnutrition
- Hypothalamic lesions
- Alcoholism
- Endocrine disorders





Patient NAME : MRS.KOMAL

Referred BY

Age/Gender : 25 Y O M O D /F

: SELF

LabNo : DPL23763

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20011725

: 23/Mar/2024 04:24PM Registration Date Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:49PM

DEPARTMENT OF BIOCHEMISTRY **ΔΡΟΙΙ Ο ΡΔCΚΔGF 24**

	APOLI	LO PACKAGE 24		
Test Name	Result	Unit	Bio. Ref. Range	Method
KIDNEY FUNCTION TEST				
Sample Type : SERUM				
SERUM UREA	23.69	mg/dL	17- 43	Urease GLDH
Blood Urea Nitrogen (BUN)	11.07	mg/dL	7 - 18	Urease
SERUM URIC ACID	3.66	mg/dL	3.5 - 7.2	Uricase/POD
SERUM CREATININE	0.68	mg/dL	0.67 - 1.17	Jaffe IDMS
SERUM TOTAL CALCIUM	10.30	mg/dL	8.8 - 10.6	Arsenazo III
SERUM SODIUM	138.2	mmol/L	136 - 146	ISE
SERUM POTASSIUM	4.10	mmol/L	3.5 - 5.1	ISE
SERUM CHLORIDE	102.5	mmol/L	101 - 109	ISE

Note:

Blood Urea Nitrogen (BUN)

Clinical Significance: Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis) and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors).

Creatinine

Clinical Significance: Serum creatinine is inversely correlated with glomerular filtration rate (GFR). Increased levels of Serum Creatinine is associated with renal dysfunction.

Calcium

Serum Calcium levels are used to monitor and diagnose a wide range of diseases of bone, kidney, parathyroid gland, or gastrointestinal tract. Calcium levels may also reflect abnormal vitamin D or protein levels. Hypocalcemia or low serum calcium levels is associated with absent or decreased function of the parathyroid glands, impaired vitamin-D synthesis, low dietary intake and chronic renal failure. Hypercalcemia is due to increased mobilization of calcium from the skeletal system or increased intestinal absorption. It is usually seen in case of primary hyperparathyroidism (pHPT) or bone metastasis of carcinoma of the breast, prostate, thyroid gland, or lung.

Sodium

Clinical Significance: Serum Sodium estimation is performed to assess acid-base balance, water balance, water intoxication, and dehydration.

Potassium



MBBS, DNB Pathology Sr. Consultant (HMC.9669)



Patient NAME : MRS.KOMAL

Age/Gender : 25 Y O M O D /F

LabNo : DPL23763

Refer Lab/Hosp : APOLLO CLINIC

: SELF

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:49PM

DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 24

Test Name Result Unit Bio. Ref. Range Method

Clinical Significance: Potassium (K+) is the major intracellular cation. It regulates neuromuscular excitability, heart contractility, intracellular fluid volume, and hydrogen ion concentration. High levels of serum Potassium is seen in acute renal disease and end-stage renal failure due to decreased excretion. Levels are also high during the diuretic phase of acute tubular necrosis, during administration of non-potassium sparing diuretic therapy, and during states of excess mineralocorticoid or glucocorticoid.

Chloride

Referred BY

Clinical Significance: Chloride (Cl) is the major extracellular anion and it has an important role in maintaining proper body water distribution, osmotic pressure, and normalanion-cation balance in the extracellular fluid compartment. Chloride is increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Hyperchloremia acidosis may be a sign of severe renal tubular pathology. Chloride is decreased inoverhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, aldosteronism, bromide intoxication, syndrome of inappropriate antidiuretic hormone secretion, and conditions associated with expansion of extracellular fluid volume."





Patient NAME : MRS. KOMAL
Age/Gender : 25 Y 0 M 0 D /F

LabNo : DPL23763 Referred BY : SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM Sample Collected Date : 23/Mar/2024 04:24PM

Report Generated Date : 23/Mar/2024 05:36PM

DEPARTMENT OF HORMONE ASSAYS APOLLO PACKAGE 24

	711 011	.017101010121		
Test Name	Result	Unit	Bio. Ref. Range Meth	
THYROID PROFILE (T3,T4,TSH)				
Sample Type : SERUM				
T3	1.41	ng/mL	0.79 - 1.58	CLIA
T4	9.25	μg/dl	4.9 - 11.00	CLIA
TSH	5 00	μIU/m	0.38 - 4.31	FIA

Interpretation

It is recommended to interpret serum TSH levels with thyroid hormone levels (especially T4 levels) taking into consideration the clinical status of patient. Pitfalls in the interpretation of the serum TSH alone are in patients with recent treatment for thyrotoxicosis, non-thyroidal illness(acute severe illness or chronic illness), central hypothyroidism, confounding medications.

Condition	TSH	T4	Т3	
Primary Hypothyroidism	Increased	Low	Normal /Low	
Subclinical Hypothyroidism	Increased	Normal	Normal	
Primary Hyperthyroidism	Decreased	Increased	Increased	
T3 Toxicosis	Decreased	Normal	Increased	
Subclinical Hyperthyroidism	Decreased	Normal	Normal	
Central Hyperthyroidism/ Thyroid Hormone Resistance	Increased /Normal	Increased	Increased	
Central Hypothyroidism / Non Thyroidal Illness	Decreased /Normal	Decreased	Decreased	





: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20011725

Registration Date

: 23/Mar/2024 04:24PM

Sample Collected Date

: 23/Mar/2024 04:24PM

Report Generated Date

: 23/Mar/2024 09:21PM

DEPARTMENT OF CLINICAL PATHOLOGY APOLLO PACKAGE 24

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE ROUTINE EXAMINATION				
VOLUME	30	ml	-	
COLOUR	PALE YELLOW		PALE YELLOW	
TRANSPARENCY	CLEAR		Clear	
REACTION (PH)	6.50		4.5 - 7.0	
SPECIFIC GRAVITY	1.020		1.010 - 1.030	
CHEMICAL EXAMINATION				
URINE SUGAR.	Absent		Nill	
Urine Protein	Absent		Nil	
Urine Ketones	Absent		Nil	
BLOOD	Absent		Absent	
Leukocyte esterase	Absent		Negative	
Bile pigments	Absent		Absent	
NITRITE	Absent		Negative	
UROBILINOGEN	Absent		Normal	
MICROSCOPIC EXAMINATION				
PUS CELLS	2-4	/hpf	0 - 5	
EPITHELIAL CELLS	1-2	/hpf	0 - 5	
RBCs	Absent	/hpf	Absent	
CRYSTALS	Absent		Absent	
CASTS	Absent		Absent	
OTHER	Absent			
URINE SUGAR - PP				
Sample Type : Urine				
Result	Absent		Nil	Benedicts test

INTERPRETATION:

When the glucose level in blood exceeds the renal thresholds of glucose (160-180mg/dl) glucose starts to appear in urine. Glucose in urine gets excreted in diabetes mellitus. Elevated level of glucose in urine may also be a result of renal glucosuria. Other causes of glucose in urine are hyperthyroidism, high sugar diet, liver cirrhosis.







: MRS.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23763

Referred BY

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20011725

Registration Date : 23/Mar/2024 04:24PM

Sample Collected Date : 23/Mar/2024 04: 24PM

Report Generated Date : 23/Mar/2024 09: 21PM

DEPARTMENT OF CLINICAL PATHOLOGY APOLLO PACKAGE 24

Test Name

Result

Unit

Bio. Ref. Range

Method

URINE FOR SUGAR - FASTING

Sample Type: Urine

Result

Absent

Nil

Benedicts test

INTERPRETATION:

When the glucose level in blood exceeds the renal thresholds of glucose (160-180mg/dl) glucose starts to appear in urine. Glucose in urine gets excreted in diabetes mellitus. Elevated level of glucose in urine may also be a result of renal glucosuria. Other causes of glucose in urine are hyperthyroidism, high sugar diet, liver cirrhosis.

*** End Of Report ***





: Mrs.KOMAL

Age/Gender

: 25 Y O M O D /F

LabNo

: DPL23865

Referred BY

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20011812

Registration Date : 24/Mar/2024 11:46AM

Sample Collected Date : 24/Mar/2024 11:46AM

Report Generated Date : 26/Mar/2024 06:36PM

DEPARTMENT OF CYTOPATHOLOGY

LIQUID BASED CYTOLOGY - PAP SMEAR

CASE NO:

IBC /77/2024

SPECIMEN:

LBC fluid. Received 14.0 ml of fluid with brush. Single smear prepared from the cyto

centrifuged sediment and stained with pap's stain.

Satisfactory for Evaluation

MICROSCOPIC EXAMINATION:

Transformation zone: Absent Squamous cellularity: Adequate

Inflammatory change: Moderate

Negative for intraepithelial lesion or malignancy (NILM)

DIAGNOSIS: Negative for intraepithelial lesion or malignancy (NILM)

ADVICE: Follow up.

The PAP Smear is not a diagnostic procedure and should not be used as the sole means to evaluate cervical cancer. It is a screening procedure to aid in detection of cervical cancer and its precursors.

The foundation of Liquid Based Cytology (LBC) is that it produces uniform, thin layer slides and minimizes obscuring artefacts as, blood and mucus. On balance, LBC provides consistent improvement compared with conventional PAP testing in specimen adequacy and detection of LSIL and HSIL categories.

Cervico - vaginal cytology is screened & reported as per the Bethesda 2014.

References:

- 1. Johnson J and Patnick J. 2000. Achievable standards, benchmarks for reporting, and criteria for evaluating cervical cytopathology. Revised 2nd Edition. NHSCSP Publications NHS Cancer Screening Programmes.
- 2. Bankhead C, Austoker J, Davey C. 2003. Cervical Screening Results Explained a guide for primary care. NHS Cancer Screening Programme.
- 3. Gibb RK, Martens MG. The Impact of Liquid Based Cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 2011; 4(Suppl 1):S2-S11
- 4. The Bathesda system for reporting cervical cytology, 2014, 3rd Edition.

*** End Of Report ***

